Dapagliflozin Combined with Conventional Anti-heart Failure Drugs in the Treatment of Chronic Heart Failure: A Clinical Efficacy Observation
Journal: Journal of Clinical Medicine Research DOI: 10.32629/jcmr.v6i3.4193
Abstract
Objective: To investigate the clinical efficacy of dapagliflozin combined with conventional anti-heart failure drugs in the treatment of patients with chronic heart failure. Methods: A total of 54 patients with chronic heart failure admitted between February 2022 and February 2023 were randomly divided into a control group and an observation group, with 27 cases in each group. The control group received conventional anti-heart failure drug therapy, while the observation group was additionally treated with dapagliflozin on the basis of the control group regimen. The treatment efficacy, cardiac function indicators, levels of inflammatory factors, quality of life scores, and incidence of adverse reactions were compared between the two groups. Results: The total effective rate in the observation group was higher than that in the control group; LVEF was higher than that in the control group; LVEDD, BNP levels, inflammatory factor levels, incidence of adverse reactions, and quality of life scores were lower than those in the control group (P<0.05). Conclusion: Dapagliflozin combined with conventional anti-heart failure drugs in the treatment of chronic heart failure can improve clinical efficacy, enhance cardiac function, reduce inflammatory factor levels, improve quality of life, and has good safety.
Keywords
dapagliflozin; chronic heart failure; conventional anti-heart failure drugs; efficacy observation
Full Text
PDF - Viewed/Downloaded: 1 TimesReferences
[1] Zhang Hao, Hao Xuezeng. Clinical efficacy of Yiqi Xiefei decoction tincture transdermal therapy in patients with chronic heart failure of Qi deficiency and blood stasis syndrome. Journal of Hunan University of Traditional Chinese Medicine, 2025, 45(5): 891-897.
[2] Wang Yang, Wang Fengrong. Research status of classic prescription Sini decoction in the treatment of chronic heart failure. Chinese Journal of New Drugs, 2025, 34(12): 1263-1268.
[3] Wang Shijuan, Bu Yunyun, Li Fan, et al. Clinical efficacy of Yiqi Fumai injection in elderly patients with coronary heart disease and chronic heart failure. Liaoning Journal of Traditional Chinese Medicine, 2025, 52(7): 119-122.
[4] Dong Xiaonan, Wang Jun, Mao Jianfang, et al. Clinical observation of Xinshuai No.1 combined with sacubitril valsartan in treating chronic heart failure with hypotension. Chinese Journal of Traditional Chinese Medicine, 2025, 43(2): 164-167.
[5] Wu Ying, Wang Zheng, Chen Lin, et al. Effect observation of Guiling Wenyang Lishui decoction combined with exercise rehabilitation therapy in treating Yang deficiency with water retention syndrome in chronic heart failure. Liaoning Journal of Traditional Chinese Medicine, 2025, 52(2): 103-106.
[6] Wang Jiru, Yang Hua, Yin Chunxia, et al. Mechanism study of Wusentang in treating chronic heart failure based on network pharmacology, molecular docking and experimental validation. Journal of Chinese Medicinal New Drugs and Clinical Pharmacology, 2025, 36(3): 392-404.
[7] Wei Mengzhao, Ding Jian, Liu Yulong, et al. Medication rules and mechanisms of compound patented Chinese medicine for chronic heart failure based on data mining and network pharmacology. Journal of Chinese Medicinal New Drugs and Clinical Pharmacology, 2025, 36(5): 814-824.
[8] Tang Xue, Cheng Lirong. Clinical observation of Qishen Fuling formula in treating chronic heart failure. Shandong Journal of Traditional Chinese Medicine, 2025, 44(6): 648-655.
[9] Li Min, Ju Juan, Xu Zhihong, et al. Efficacy of Gedan Shengmai Yangxin combined preparation in treating chronic heart failure patients and its effect on vascular endothelial function. Journal of Hunan University of Traditional Chinese Medicine, 2025, 45(6): 1083-1088.
[10] Tan Gang, Li Yongfang, Zhou Guangpeng. Clinical observation of ivabradine in treating end-stage renal disease patients with chronic heart failure during maintenance hemodialysis. Chinese Pharmacy, 2025, 36(1): 91-95.
[2] Wang Yang, Wang Fengrong. Research status of classic prescription Sini decoction in the treatment of chronic heart failure. Chinese Journal of New Drugs, 2025, 34(12): 1263-1268.
[3] Wang Shijuan, Bu Yunyun, Li Fan, et al. Clinical efficacy of Yiqi Fumai injection in elderly patients with coronary heart disease and chronic heart failure. Liaoning Journal of Traditional Chinese Medicine, 2025, 52(7): 119-122.
[4] Dong Xiaonan, Wang Jun, Mao Jianfang, et al. Clinical observation of Xinshuai No.1 combined with sacubitril valsartan in treating chronic heart failure with hypotension. Chinese Journal of Traditional Chinese Medicine, 2025, 43(2): 164-167.
[5] Wu Ying, Wang Zheng, Chen Lin, et al. Effect observation of Guiling Wenyang Lishui decoction combined with exercise rehabilitation therapy in treating Yang deficiency with water retention syndrome in chronic heart failure. Liaoning Journal of Traditional Chinese Medicine, 2025, 52(2): 103-106.
[6] Wang Jiru, Yang Hua, Yin Chunxia, et al. Mechanism study of Wusentang in treating chronic heart failure based on network pharmacology, molecular docking and experimental validation. Journal of Chinese Medicinal New Drugs and Clinical Pharmacology, 2025, 36(3): 392-404.
[7] Wei Mengzhao, Ding Jian, Liu Yulong, et al. Medication rules and mechanisms of compound patented Chinese medicine for chronic heart failure based on data mining and network pharmacology. Journal of Chinese Medicinal New Drugs and Clinical Pharmacology, 2025, 36(5): 814-824.
[8] Tang Xue, Cheng Lirong. Clinical observation of Qishen Fuling formula in treating chronic heart failure. Shandong Journal of Traditional Chinese Medicine, 2025, 44(6): 648-655.
[9] Li Min, Ju Juan, Xu Zhihong, et al. Efficacy of Gedan Shengmai Yangxin combined preparation in treating chronic heart failure patients and its effect on vascular endothelial function. Journal of Hunan University of Traditional Chinese Medicine, 2025, 45(6): 1083-1088.
[10] Tan Gang, Li Yongfang, Zhou Guangpeng. Clinical observation of ivabradine in treating end-stage renal disease patients with chronic heart failure during maintenance hemodialysis. Chinese Pharmacy, 2025, 36(1): 91-95.
Copyright © 2025 Zhifu Bao
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License